Photocure ASA : Market Maker Agreement

PHOTOCURE NOMINATES MARKET MAKER ON OSLO STOCK EXCHANGE

Oslo, Norway, 28 November 2011: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces it has entered into a Market Making Agreement with Spare Bank 1 Markets AS for the Company`s shares.

The aim of the agreement is to improve the market conditions for Photocure's shares via a more transparent and effective pricing and increased liquidity. The Agreement is in accordance with the standard requirements of the Oslo Stock Exchange. The Market Making Agreement will take effect as of 29 November 2011.

For further information contact:

Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology. Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.